Related Experiment Video
Updated: Jun 29, 2025
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms
Chaoyu Pang1, Yongzheng Li1, Ming Shi1
1Division of Pancreatic Surgery, Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
CXC chemokine receptor 4 (CXCR4) is highly expressed in Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3 (GEP-NENs G3) tumors, particularly in neuroendocrine carcinoma (NEC) compared to neuroendocrine tumor (NET) G3. While CXCR4 shows differential expression, it did not correlate with patient prognosis in this study.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- CXC chemokine receptor 4 (CXCR4) is implicated in malignant tumor progression and metastasis.
- The role of CXCR4 in Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3 (GEP-NENs G3) remains largely uncharacterized.
- Understanding CXCR4 expression is crucial for GEP-NENs G3 diagnosis and potential therapeutic strategies.
Purpose of the Study:
- To investigate the expression patterns of CXCR4 in GEP-NENs G3.
- To evaluate the clinical significance and prognostic value of CXCR4 in GEP-NENs G3.
- To differentiate between neuroendocrine tumor (NET) G3 and neuroendocrine carcinoma (NEC) using CXCR4 expression.
Main Methods:
- Retrospective analysis of clinical and pathological data from 100 GEP-NENs G3 patients.
- Immunohistochemistry (IHC) to assess CXCR4 expression in tumor tissues and adjacent normal tissues.
- Kaplan-Meier (K-M) survival analysis to determine the prognostic impact of CXCR4.
Main Results:
- CXCR4 was significantly overexpressed in GEP-NENs G3 tumors compared to adjacent tissues (P<0.001).
- Neuroendocrine carcinoma (NEC) exhibited higher CXCR4 expression than neuroendocrine tumor (NET) G3 (P=0.038).
- No significant correlation was found between high or low CXCR4 expression and overall survival in GEP-NENs G3 or NEC patients (P=0.920, P=0.842).
Conclusions:
- CXCR4 demonstrates differential expression between tumor and adjacent tissues, and between NEC and NET G3.
- CXCR4 may serve as a valuable immunohistochemical (IHC) diagnostic marker for GEP-NENs G3.
- Further multi-center studies with larger cohorts and longer follow-up are warranted to confirm the prognostic implications of CXCR4.
